STOCK TITAN

Veraxa Biotech sets Dec. 10 vote on KPMG as auditor

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Veraxa Biotech AG (VRXA) called an Extraordinary General Meeting for December 10, 2026, at 11:00 AM at Walder Wyss AG in Zurich; doors open at 10:30 AM. The Board of Directors proposes that shareholders elect KPMG AG as statutory auditor for the 2026 business year, after BDO AG announced its resignation as auditor.

Filing Explained

For this meeting, only people entered in Veraxa’s electronic share register on November 13, 2026 are recognized as shareholders; they may appoint a representative, including an independent proxy through the shareholder platform.

Meeting date December 10, 2026 Extraordinary General Meeting
Record date November 13, 2026 Determines who is entitled to receive notice of the meeting
Meeting time 11:00 AM Doors open at 10:30 AM
statutory auditor regulatory
"Election of KPMG AG as statutory auditor for the 2026 business year"
A statutory auditor is an independent, legally required accountant who examines a company’s financial records and issues an official opinion on whether the financial statements give a true and fair view. Investors rely on this check as a trusted third-party stamp—like a certified inspection—because it reduces the chance that errors, omissions or rule-breaking will mislead people making investment decisions.
record date regulatory
"fixed November 13, 2026 as the record date"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
independent proxy regulatory
"appoint an independent proxy on the shareholder platform"
An independent proxy is a neutral person or third-party firm appointed to collect and cast shareholders’ votes at a corporate meeting when owners cannot attend in person. It matters to investors because it helps ensure votes are handled fairly and free from insider influence; think of it as a trusted messenger who follows your instructions so your voice counts in decisions that can affect company strategy and share value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can VRXA shareholders be represented at the December 10, 2026 meeting?

Shareholders may appoint a proxy; an appointed shareholder proxy must present a legally valid power of attorney. Alternatively, shareholders may appoint an independent proxy through the shareholder platform.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-43342

 

 

 

Veraxa Biotech AG

 

 

 

Talacker 35

8001 Zurich, Switzerland

(Address of principal executive office)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

Extraordinary General Meeting of Shareholders

 

On November 18, 2026, Veraxa Biotech AG (the “Company”) issued a notice for its Extraordinary General Meeting of Shareholders to be held on December 10, 2026 (the “Meeting”). The Company fixed November 13, 2026 as the record date for determination of persons entitled to receive notice of the Meeting.

 

A copy of the notice is attached as Exhibit 99.1 to this report on Form 6-K and is incorporated by reference herein.

 

EXHIBIT INDEX

 

Exhibit   Description of Exhibit
99.1   Meeting Notice dated November 18, 2026

 

1

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VERAXA BIOTECH AG
   
Date: November 19, 2026 By: /s/ Christoph Antz
  Name:  Christoph Antz
  Title: Chief Executive Officer

 

  By: /s/ Oliver Baumann
  Name:  Oliver Baumann
  Title: Chairman of the Board of Directors

 

2

 

Exhibit 99.1

 

 

 

Zürich, den 18. November 2026

Zurich, 18 November 2026

 

Veraxa Biotech AG, Zürich

 

Einladung zur ausserordentlichen Generalversammlung der Aktionäre am Donnerstag, 10. Dezember 2026

Invitation to the Extraordinary General Meeting of Shareholders on Thursday, 10 December 2026

 

Sehr geehrte Aktionärinnen und Aktionäre,

Dear Shareholders,

 

Wir freuen uns, Sie zur ausserordentlichen Generalversammlung der Aktionärinnen und Aktionäre der Veraxa Biotech AG einzuladen.

We are pleased to invite you to the Extraordinary General Meeting of Shareholders of Veraxa Biotech AG.

 

Datum: 10. Dezember 2026
Date: 10 December 2026
Uhrzeit: 11:00 Uhr (Einlass ab 10:30 Uhr)
Time 11:00 AM (doors open at 10:30 AM)
Ort / Place: Walder Wyss AG, Seefeldstrasse 123, 8008 Zürich

 

TRAKTANDUM

AGENDA

 

Wahl von KPMG AG als Revisionsstelle für das Geschäftsjahr 2026

Election of KPMG AG as statutory auditor for the 2026 business year

 

Die BDO AG, in Baden, hat ihren Rücktritt als Revisionsstelle erklärt. Der Verwaltungsrat beantragt der Generalversammlung, KPMG AG, mit Sitz in Zürich, als neue Revisionsstelle für das Geschäftsjahr 2026 zu wählen.

BDO AG, in Baden, has announced its resignation as auditor. The Board of Directors proposes that the Shareholders’ Meeting elect KPMG AG, Zurich, as the new auditor for the 2026 business year.

 

 

Veraxa Biotech AG, Talacker 35, 8001 Zürich, Schweiz. Tel. +41 44 385 84 60,
investors@veraxa.com, www.veraxa.com, HR Zürich CHE-441.201.868

 

 

 

A) Einzelweisungen zu in der Einladung bekannt gegebenen Anträgen des Verwaltungsrates zu den Verhandlungsgegenständen (Traktanden)

A) Individual instructions regarding the Board of Directors’ proposals on the agenda items announced in the invitation

 

Traktandum       Ja   Nein   Enthaltung
Agenda       Yes   No   Abstention
1  

Wahl von KPMG AG als Revisionsstelle für das Geschäftsjahr 2026

Election of KPMG AG as statutory auditor for the 2026 business year

  ☐   ☐   ☐

 

B) Allgemeine Weisung
B) General Directive

 

Für den Fall, dass an der Generalversammlung über in der Einladung nicht angekündigte Anträge und/oder über neue Verhandlungsgegenstände abgestimmt wird, beauftrage und ermächtige ich den unabhängigen Stimmrechtsvertreter, sich wie folgt zu verhalten:

In the event that a resolution is put to a vote at the shareholders’ meeting regarding motions not announced in the notice of meeting and/or new items on the agenda, I hereby instruct and authorize the independent proxy to act as follows:

 

  ☐ Im Sinne des Antrags des Verwaltungsrates
    In accordance with the motion of the Board of Directors
     
  ☐ Gegen nicht angekündigte Anträge und Anträge zu neuen Verhandlungsgegenständen
    Against unannounced motions and motions regarding new agenda items
     
  ☐ Stimmenthaltung
    Abstention

 

Als Aktionärinnen und Aktionäre werden diejenigen Personen anerkannt, welche per 13. November 2026 im elektronischen Aktienbuch der Veraxa Biotech AG eingetragen sind. Die gegenseitige Vertretung von Aktionären ist statthaft. Ein zur Vertretung berufener Aktionär hat eine rechtsgültige Vollmacht seitens des vertretenen Aktionärs mitzubringen. Ein entsprechendes Formular haben wir Ihnen zu dieser Einladung beigelegt. Alternativ können Sie auf der Aktionärsplattform www.aequitec.ch einen unabhängigen Stimmrechtsvertreter mandatieren.

Shareholders are defined as those individuals who are registered in the electronic share register of Veraxa Biotech AG as of 13 November 2026. Shareholders may appoint proxies to represent them. A shareholder appointed as a proxy must present a legally valid power of attorney from the shareholder they are representing. We have enclosed the appropriate form with this invitation. Alternatively, you can appoint an independent proxy on the shareholder platform www.aequitec.ch.

 

 

Veraxa Biotech AG, Talacker 35, 8001 Zürich, Schweiz. Tel. +41 44 385 84 60,
investors@veraxa.com, www.veraxa.com, HR Zürich CHE-441.201.868

 

2

 

Wir freuen uns, Sie am 10. Dezember 2026 in Zürich begrüssen zu dürfen.

We look forward to welcoming you in Zurich on 10 December 2026.

 

Freundliche Grüsse

Kind regards

 

/s/ Oliver R. Baumann  
Oliver R. Baumann  
Präsident des Verwaltungsrates  
Chairman of the Board of Directors  

 

 

Veraxa Biotech AG, Talacker 35, 8001 Zürich, Schweiz. Tel. +41 44 385 84 60,
investors@veraxa.com, www.veraxa.com, HR Zürich CHE-441.201.868

 

3

Filing Exhibits & Attachments

2 documents

Keep reading